Free Newsletter
FDA opens kimono on agency performance
The FDA is furthering its journey toward transparency with the launch of FDA-TRACK, a multi-level performance management system. "TRACK" stands for transparency, results, accountability, credibility and knowledge-sharing.
The idea is to encourage agency accountability by measuring how well managers and employees meet their goals. In addition, the system provides a way for the public to monitor agency activities.
FDA-TRACK analyzes performance at four levels: Agency, center, program and project. At the center level, for example, it measures the regulator's attempts to offer guidance by tracking the number of technical publications drafted. A program-level example involves monitoring the percentage of 510(k) decisions that meet the 90-day Medical Device User Fee Act goal. And project-level performance is tracked via achievement of stated milestones.
Performance measurement stats are reported monthly; the monthly stats are analyzed quarterly and presented to leadership. The FDA-TRACK Internet site provides public access to program- and project-level activities.
- see the release
- here's the FDA-Track Internet page
Related Articles:
FDA looks for transparency options
FDA draws back the veil
Regulators mull pros, cons of transparency efforts
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: